EUDA ends $10M at-the-market share offering program

EUDA Health Holdings Limited is suspending and terminating its at-the-market equity offering program with Chardan Capital Markets LLC.

Rhea-AI Filing Summary

EUDA Health Holdings Limited is suspending and terminating its at-the-market equity offering program with Chardan Capital Markets LLC. The company had the ability to offer and sell up to $10,000,000 of ordinary shares under an At The Market Offering Agreement and related prospectus supplements.

EUDA sent a termination notice for the ATM Agreement on June 5, 2026, with termination to take effect on July 22, 2026 after a 30-business-day period. The ATM Offering has been suspended effective June 10, 2026, and EUDA plans to file a prospectus supplement reducing the number of shares offered to zero. As of this report, no ordinary shares have been sold under the ATM program.

Key Figures

ATM capacity: $10,000,000 ordinary shares Termination effective date: July 22, 2026 Suspension date: June 10, 2026 +3 more

6 metrics

ATM capacity $10,000,000 ordinary shares Maximum size of at-the-market offering under ATM Agreement

Termination effective date July 22, 2026 Effective date of ATM Agreement termination after 30 business days

Suspension date June 10, 2026 Date ATM Offering was suspended

Termination notice date June 5, 2026 Date EUDA sent termination notice to Chardan

Business day period 30 business days Notice period before ATM Agreement termination becomes effective

Shares sold under ATM 0 ordinary shares Total shares sold under ATM Agreement and Filed Prospectus Supplements

Key Terms

At The Market Offering Agreement, prospectus supplement, Registration Statement on Form F-3, at-the-market offering

4 terms

At The Market Offering Agreement financial

"entered into an At The Market Offering Agreement (the “ATM Agreement”) with Chardan"

An at-the-market offering agreement is a contract that lets a company sell newly issued shares directly into the open market through a broker, at whatever price the stock is trading at that moment. For investors this matters because it can increase the number of shares available (which may dilute existing ownership) while providing a flexible, often faster way for the company to raise cash without fixing a price, similar to a vendor selling small batches at current market stalls rather than setting a single fixed price.

prospectus supplement regulatory

"filed a prospectus supplement on each of June 24, 2025 and January 23, 2026"

A prospectus supplement is an additional document provided alongside a company's main offering details, offering updated or extra information about a specific financial product being sold. It helps investors understand the latest terms, risks, and details of the investment, similar to how an update or revision clarifies or expands on original instructions, ensuring they have current and complete information before making a decision.

Registration Statement on Form F-3 regulatory

"formed a part of the Company’s Registration Statement on Form F-3 (File No. 333-282723)"

A registration statement on Form F-3 is a streamlined filing used by eligible foreign companies to register securities for sale in the U.S., often as a “shelf” that lets them offer shares quickly when market conditions are right. For investors it matters because it signals that the company can raise capital on short notice—potentially increasing liquidity but also the risk of share dilution if new stock is issued—similar to a company keeping a pre-approved credit line ready to use.

at-the-market offering financial

"relating to the offer and sale of up to $10,000,000 ordinary shares in an “at-the-market” offering"

An at-the-market offering is a method companies use to sell new shares of stock directly into the open market over time, rather than all at once. This allows them to raise money gradually, similar to selling small pieces of a product instead of a large batch. For investors, it means the company can access funding more flexibly, but it may also increase the supply of shares and influence the stock’s price.

FAQ

AI-generated questions and answers. How Rhea-AI works. Not financial advice.

What did EUDA (EUDA) announce in its June 2026 Form 6-K?

EUDA announced it is suspending and terminating its at-the-market equity offering program with Chardan. The company will reduce the number of shares offered under related prospectus supplements to zero and confirmed that no ordinary shares have been sold under this ATM Agreement.

How large was EUDA’s (EUDA) at-the-market offering program?

The ATM program allowed EUDA to offer and sell up to $10,000,000 of ordinary shares. This capacity was established through an At The Market Offering Agreement with Chardan and related prospectus supplements filed in June 2025 and January 2026 under a Form F-3 registration statement.

When will EUDA’s (EUDA) ATM Agreement with Chardan terminate?

EUDA sent Chardan a written notice to terminate the ATM Agreement on June 5, 2026. Under the agreement’s terms, the termination becomes effective on July 22, 2026, which is thirty business days after the date of the termination notice sent by the company.

When did EUDA (EUDA) suspend its at-the-market offering?

EUDA suspended its at-the-market offering effective June 10, 2026. The suspension applies while the termination notice period runs, and the company also plans to file a prospectus supplement reducing the number of shares that may be offered under the ATM-related prospectus supplements to zero.

Has EUDA (EUDA) sold any shares under its ATM Agreement?

As of the date of the report, EUDA has not sold any ordinary shares under the ATM Agreement or the related prospectus supplements. The company is now suspending the program and will reduce the number of shares offered under those prospectus supplements to zero.

What registration statement supported EUDA’s (EUDA) ATM offering?

EUDA’s ATM offering was conducted under a Registration Statement on Form F-3, File No. 333-282723. That registration statement was filed on October 18, 2024 and declared effective on November 4, 2024, with later prospectus supplements describing the at-the-market share offering.

AI-generated analysis. How Rhea-AI works. Not financial advice.

Form 6-K: How Foreign Companies Report to the SEC →

See more from StockTitan in Google Search and AI answers. Adds StockTitan as a preferred source · opens Google

Add on Google Not now

Accepted by SEC EDGAR 06/10/2026 - 07:00 AM EDT Learn about SEC filing dates

UNITED STATES

SECURITIES AND EXCHANGE COMMISSION

Washington, D.C. 20549

Form 6-K

REPORT OF FOREIGN PRIVATE ISSUER

PURSUANT TO RULE 13a-16 OR 15d-16

UNDER THE SECURITIES EXCHANGE ACT OF 1934

For the month of June 2026

Commission File Number: 001-40678

EUDA Health Holdings Limited

(Exact Name of Registrant as Specified in its Charter)

60 Kaki Bukit Place, #03-01 Eunos Techpark, Singapore 415979

(Address of Principal Executive Offices and Zip Code)

Registrant’s telephone number, including area code: +65 6327 1110

Indicate by check mark whether the registrant files or will file annual reports under cover of Form 20-F or Form 40-F. Form 20-F ☒ Form 40-F ☐

Suspension of ATM Offering; Termination of At The Market Offering Agreement

As previously reported, on June 23, 2025, EUDA Health Holdings Limited (“EUDA” or the “Company”) entered into an At The Market Offering Agreement (the “ATM Agreement”) with Chardan Capital Markets LLC (“Chardan”). The Company filed a prospectus supplement on each of June 24, 2025 and January 23, 2026 (each, the “Filed Prospectus Supplement”) relating to the offer and sale of up to $10,000,000 ordinary shares (the “Shares”) in an “at-the-market” offering (the “ATM Offering”) pursuant to the ATM Agreement. Each Filed Prospectus Supplement formed a part of the Company’s Registration Statement on Form F-3 (File No. 333-282723), which was filed with the Securities and Exchange Commission on October 18, 2024 and declared effective on November 4, 2024. On June 5, 2026, the Company sent Chardan a written notice to terminate the ATM Agreement. Pursuant to the terms of the ATM Agreement, this termination will take effect on July 22, 2026 (i.e., after thirty (30) business days from the date of the termination notice). In the meantime, the Company has suspended the ATM Offering, effective as of June 10, 2026. The Company will file a prospectus supplement reducing the number of Shares to be offered under the Filed Prospectus Supplements to zero. As of the date of this report, no ordinary shares have been sold under the ATM Agreement or the Filed Prospectus Supplements.

2

SIGNATURES

Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned, hereunto duly authorized.

Dated: June 10, 2026
	EUDA Health Holdings Limited
	By:	/s/ Alfred Lim
	Name:	Alfred Lim
	Title:	Chief Executive Officer

3